Sprint Corp. Ratings Still on CreditWatch With Positive Implications Following Announcement Jan 00

  • ID: 2083994
  • January 2000
  • Standard & Poors
1 of 3


  • Sprint Capital Corp.
  • Sprint Nextel Corp.
  • MORE

NEW YORK (Standard & Poor's CreditWire) Jan. 27, 2000--Standard & Poor's ratings on Sprint Corp. and unit Sprint Capital Corp. remain on CreditWatch with positive implications (see list below) following Sprint's announcement that it is selling its share in Global One to Deutsche Telekom AG and France Telecom for $1.13 billion in cash and repayment of $276 million in debt. Proceeds from the sale are expected to offset some future financing needs for operating and capital requirements. Sprint's ratings were placed on CreditWatch with positive implications on Oct. 5, 1999, due to its entering a definitive agreement to merge with MCI WorldCom Inc. The merger is expected to close in the second half 2000 subject to approval by shareholders and...

Companies mentioned in this report are:
- Sprint Nextel Corp.
- Sprint Capital Corp.

Action: CreditWatch Update

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Sprint Nextel Corp.
- Sprint Capital Corp.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.